{"success":true,"data":{"pressRelease":{"id":"154600","rtpr_id":"nNFC6zTgjZ-20260928","ticker":"DOCS","exchange":"NYSE","all_tickers":["DOCS"],"title":"Robbins LLP is Investigating Allegations that Doximity, Inc. Failed to Disclose to Investors it Was Losing Market Share to its Competitors With More Favorable Pricing and Engagement Models","author":"Newsfile Corp","published_at":"2026-09-28T20:35:13.535Z","article_body":"San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder\nrights law firm Robbins LLP (https://api.newsfilecorp.com/redirect/0p0gXuw0We)\nreminds investors that a class action was filed on behalf of persons and\nentities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS)\ncommon stock August 8, 2024 and May 13, 2026, inclusive (the \"Class Period\").\nDoximity is a digital platform for medical professionals that combines health\ncare news, workflow products, and clinician networking.\n\nThe complaint alleges that Doximity failed to disclose to investors that it\nwas losing market share to its competitors with more favorable pricing and\nengagement models.\n\nInvestors who suffered significant losses during the Class Period may be\neligible to participate in the lawsuit and should contact\n(https://api.newsfilecorp.com/redirect/RYqJ3sWKz8) Robbins LLP for information\nbefore the November 16, 2026, lead plaintiff deadline.\n\nListen to our podcast (https://api.newsfilecorp.com/redirect/WAMBNHWbDK).\n\nWhy Was Doximity Sued?\n\nThe complaint alleges that during the Class Period defendants claimed the\nCompany's Newsfeed was its \"biggest revenue driver.\" Specifically, defendants\nclaimed that the Company's growth was \"led by our Newsfeed, which is both our\nmost used and most monetized product\" and told investors that the Newsfeed was\nconsistently \"reach[ing] new highs,\" with \"an all-time record of quarterly\nactive prescribers and double-digit growth in the number of articles read or\ntapped.\" In addition, Doximity touted its \"deep engagement,\" assuring\ninvestors that Doximity does not \"bombard physicians with ads and messages in\nhopes of getting lucky\" and assured investors that \"[Doximity does not] have\nan e-newsletter product.\" In truth, Doximity overstated the impact that its\nNewsfeed had on its revenue growth, and the Company was losing market share to\nits competitors with more favorable pricing and engagement models.\nAdditionally, notwithstanding its frequent statements to the contrary,\nDoximity relied heavily on both banner ads and email newsletters as\nadvertising methods.\n\nWhy Did Doximity Stock Drop?\n\nPlaintiff alleges that on November 6, 2025, despite reporting strong second\nquarter results, Doximity expressed a degree of caution regarding the outlook\nfor ad spending and implied a slowdown in sales growth in the second half of\nthe 2026 fiscal year, which ended on March 31, 2026. As a result of these\ndisclosures, the price of Doximity common stock declined by $8.29 per share,\nor 13%.\n\nThen, on February 5, 2026, Doximity lowered its revenue guidance for 2026 full\nfiscal year, which ended on March 31, 2026, and announced that its sales\ngrowth had decelerated while its net income had contracted, which will\nnegatively impact its 2026 fiscal fourth quarter. Following these poor\nfinancial results, analysts noted that \"uncertainty is lingering. This is not\nwidespread, meaning not all pharma[ceutical] clients are holding back\" on\ntheir advertising spend. Analysts also began to posit that the reason for\nDoximity's slowing growth was that the Company was actually losing market\nshare to its competitors. Specifically, an analyst at Evercore noted that\nolder companies, such as Doximity, \"are losing share while programmatic,\nsocial, and other new formats are gaining share.\" As a result of these\ndisclosures, the price of Doximity common stock declined by $5.59 per share,\nor 17%.\n\nThen, on May 13, 2026, Doximity announced that it missed its already-reduced\nrevenue guidance and projected a significantly slower pace of growth for its\n2027 fiscal year, which ends on March 31, 2027. As a result, several analysts\ndowngraded Doximity stock citing issues specific to the Company's business.\nFor example, Freeman Capital Markets described the news as \"a tough pill to\nswallow\" as shares fell to \"an all-time low\" and Jefferies placed the stock in\nthe \"penalty box.\" Leerink Partners also put Doximity \"in the penalty box\"\nfollowing the \"eye-catching\" guidance paired with the \"shock value\" of \"[a]ll\nof the dynamics that lead to the guidance, including market softness, timing\nof commitments and the spend to ramp its AI products.\" RBC Capital Markets\nnoted that Doximity's stalled net revenue retention suggested an \"increasingly\ncompetitive market.\" As a result of these disclosures, the price of Doximity\ncommon stock declined by $5.38 per share, or 23%.\n\nWho May Be Eligible to Participate in the Doximity Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nDoximity, Inc. common stock between August 8, 2024 and May 13, 2026. Investors\nwho suffered losses during that period may have legal rights under the federal\nsecurities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Stockholders who wish to lead\nthe class action should contact Robbins LLP before the November 16, 2026, lead\nplaintiff deadline.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nWhy Robbins LLP?\n\nA recognized leader in shareholder rights litigation, Robbins LLP\n(https://api.newsfilecorp.com/redirect/qpMVWuawmk) represents investors in\nsecurities fraud and shareholder derivative litigation. We have helped restore\nmore than $2 billion in value to shareholders and secured some of the largest\nrecoveries in shareholder derivative litigation history.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Doximity, Inc. settles or to receive\nfree alerts when corporate executives engage in wrongdoing, sign up for Stock\nWatch (https://api.newsfilecorp.com/redirect/noMXYIykJR) today.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Doximity, Inc. securities\nclass action may contact Robbins LLP by submitting\n(https://api.newsfilecorp.com/redirect/KLwDnSwgZj) an inquiry, emailing\n(mailto:adumas@robbinsllp.com) attorney Aaron Dumas, Jr., or calling (800)\n350-6003.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\nContact:\nAaron Dumas, Jr.\nRobbins LLP\n5060 Shoreham Pl., Ste. 300\nSan Diego, CA 92122\nadumas@robbinsllp.com\n(800) 350-6003\nwww.robbinsllp.com\n\nFacebook (https://api.newsfilecorp.com/redirect/xErQehazr7)\nLinkedIn (https://api.newsfilecorp.com/redirect/7nNxvSe0DY) \n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316400","article_body_html":"","raw_payload":{"data":{"id":"nNFC6zTgjZ-20260928","title":"Robbins LLP is Investigating Allegations that Doximity, Inc. Failed to Disclose to Investors it Was Losing Market Share to its Competitors With More Favorable Pricing and Engagement Models","author":"Newsfile Corp","ticker":"DOCS","created":"2026-09-28T20:35:13.535Z","tickers":["DOCS"],"exchange":"NYSE","article_body":"San Diego, California--(Newsfile Corp. - September 28, 2026) - Shareholder\nrights law firm Robbins LLP (https://api.newsfilecorp.com/redirect/0p0gXuw0We)\nreminds investors that a class action was filed on behalf of persons and\nentities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS)\ncommon stock August 8, 2024 and May 13, 2026, inclusive (the \"Class Period\").\nDoximity is a digital platform for medical professionals that combines health\ncare news, workflow products, and clinician networking.\n\nThe complaint alleges that Doximity failed to disclose to investors that it\nwas losing market share to its competitors with more favorable pricing and\nengagement models.\n\nInvestors who suffered significant losses during the Class Period may be\neligible to participate in the lawsuit and should contact\n(https://api.newsfilecorp.com/redirect/RYqJ3sWKz8) Robbins LLP for information\nbefore the November 16, 2026, lead plaintiff deadline.\n\nListen to our podcast (https://api.newsfilecorp.com/redirect/WAMBNHWbDK).\n\nWhy Was Doximity Sued?\n\nThe complaint alleges that during the Class Period defendants claimed the\nCompany's Newsfeed was its \"biggest revenue driver.\" Specifically, defendants\nclaimed that the Company's growth was \"led by our Newsfeed, which is both our\nmost used and most monetized product\" and told investors that the Newsfeed was\nconsistently \"reach[ing] new highs,\" with \"an all-time record of quarterly\nactive prescribers and double-digit growth in the number of articles read or\ntapped.\" In addition, Doximity touted its \"deep engagement,\" assuring\ninvestors that Doximity does not \"bombard physicians with ads and messages in\nhopes of getting lucky\" and assured investors that \"[Doximity does not] have\nan e-newsletter product.\" In truth, Doximity overstated the impact that its\nNewsfeed had on its revenue growth, and the Company was losing market share to\nits competitors with more favorable pricing and engagement models.\nAdditionally, notwithstanding its frequent statements to the contrary,\nDoximity relied heavily on both banner ads and email newsletters as\nadvertising methods.\n\nWhy Did Doximity Stock Drop?\n\nPlaintiff alleges that on November 6, 2025, despite reporting strong second\nquarter results, Doximity expressed a degree of caution regarding the outlook\nfor ad spending and implied a slowdown in sales growth in the second half of\nthe 2026 fiscal year, which ended on March 31, 2026. As a result of these\ndisclosures, the price of Doximity common stock declined by $8.29 per share,\nor 13%.\n\nThen, on February 5, 2026, Doximity lowered its revenue guidance for 2026 full\nfiscal year, which ended on March 31, 2026, and announced that its sales\ngrowth had decelerated while its net income had contracted, which will\nnegatively impact its 2026 fiscal fourth quarter. Following these poor\nfinancial results, analysts noted that \"uncertainty is lingering. This is not\nwidespread, meaning not all pharma[ceutical] clients are holding back\" on\ntheir advertising spend. Analysts also began to posit that the reason for\nDoximity's slowing growth was that the Company was actually losing market\nshare to its competitors. Specifically, an analyst at Evercore noted that\nolder companies, such as Doximity, \"are losing share while programmatic,\nsocial, and other new formats are gaining share.\" As a result of these\ndisclosures, the price of Doximity common stock declined by $5.59 per share,\nor 17%.\n\nThen, on May 13, 2026, Doximity announced that it missed its already-reduced\nrevenue guidance and projected a significantly slower pace of growth for its\n2027 fiscal year, which ends on March 31, 2027. As a result, several analysts\ndowngraded Doximity stock citing issues specific to the Company's business.\nFor example, Freeman Capital Markets described the news as \"a tough pill to\nswallow\" as shares fell to \"an all-time low\" and Jefferies placed the stock in\nthe \"penalty box.\" Leerink Partners also put Doximity \"in the penalty box\"\nfollowing the \"eye-catching\" guidance paired with the \"shock value\" of \"[a]ll\nof the dynamics that lead to the guidance, including market softness, timing\nof commitments and the spend to ramp its AI products.\" RBC Capital Markets\nnoted that Doximity's stalled net revenue retention suggested an \"increasingly\ncompetitive market.\" As a result of these disclosures, the price of Doximity\ncommon stock declined by $5.38 per share, or 23%.\n\nWho May Be Eligible to Participate in the Doximity Class Action?\n\nThe lawsuit seeks to represent investors who purchased or otherwise acquired\nDoximity, Inc. common stock between August 8, 2024 and May 13, 2026. Investors\nwho suffered losses during that period may have legal rights under the federal\nsecurities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a court-appointed investor who represents the interests\nof all class members throughout the litigation. Stockholders who wish to lead\nthe class action should contact Robbins LLP before the November 16, 2026, lead\nplaintiff deadline.\n\nServing as lead plaintiff is not required to share in any potential recovery.\nInvestors who do not seek appointment may remain absent class members if the\ncase proceeds and later resolves successfully.\n\nDoes It Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis.\n\nWhy Robbins LLP?\n\nA recognized leader in shareholder rights litigation, Robbins LLP\n(https://api.newsfilecorp.com/redirect/qpMVWuawmk) represents investors in\nsecurities fraud and shareholder derivative litigation. We have helped restore\nmore than $2 billion in value to shareholders and secured some of the largest\nrecoveries in shareholder derivative litigation history.\n\n\"Companies have an obligation to provide investors with complete and accurate\ninformation so that markets can function fairly and efficiently,\" said Brian\nJ. Robbins, Founding Partner of Robbins LLP.\n\nTo be notified if a class action against Doximity, Inc. settles or to receive\nfree alerts when corporate executives engage in wrongdoing, sign up for Stock\nWatch (https://api.newsfilecorp.com/redirect/noMXYIykJR) today.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Doximity, Inc. securities\nclass action may contact Robbins LLP by submitting\n(https://api.newsfilecorp.com/redirect/KLwDnSwgZj) an inquiry, emailing\n(mailto:adumas@robbinsllp.com) attorney Aaron Dumas, Jr., or calling (800)\n350-6003.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\nContact:\nAaron Dumas, Jr.\nRobbins LLP\n5060 Shoreham Pl., Ste. 300\nSan Diego, CA 92122\nadumas@robbinsllp.com\n(800) 350-6003\nwww.robbinsllp.com\n\nFacebook (https://api.newsfilecorp.com/redirect/xErQehazr7)\nLinkedIn (https://api.newsfilecorp.com/redirect/7nNxvSe0DY) \n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316400"},"type":"article","timestamp":"2026-09-28T20:35:13.598541893Z","server_sent_at_ms":1790627713598},"received_at":"2026-09-28T20:35:13.670Z","source_url":"https://www.newsfilecorp.com/release/316400"},"analysis":{"id":"143361","press_release_id":"154600","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":["alleged misrepresentation of Newsfeed revenue contribution during class period","recapped guidance cuts and 13%, 17%, and 23% single-day stock declines"],"eventType":"legal_litigation","narrative":"Robbins LLP issued a shareholder-solicitation notice reminding DOCS investors of the November 16, 2026 lead plaintiff deadline in a securities class action covering purchases from August 8, 2024 through May 13, 2026.\n\nThe complaint alleges Doximity overstated its Newsfeed's contribution to revenue growth while losing market share to competitors with more favorable pricing and engagement models.\n\nThe release recaps three prior stock declines (13%, 17%, and 23%) tied to earlier company disclosures; the notice itself is law-firm marketing, not new information from Doximity.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation — suppress."},"keyFigures":{"customDimensions":{"class_period":"August 8, 2024 to May 13, 2026","lead_plaintiff_deadline":"November 16, 2026"}},"quotedText":"The complaint alleges that Doximity failed to disclose to investors that it was losing market share to its competitors with more favorable pricing and engagement models.","namedEntities":{"people":[{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"},{"name":"Aaron Dumas, Jr.","role":"attorney contact, Robbins LLP"}],"products":["Newsfeed"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Doximity, Inc.","ticker":"DOCS","relationship":"litigation target / named issuer"},{"name":"Evercore","relationship":"analyst cited"},{"name":"Jefferies","relationship":"analyst cited"},{"name":"Leerink Partners","relationship":"analyst cited"},{"name":"RBC Capital Markets","relationship":"analyst cited"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation (Robbins LLP) reminding investors of the lead plaintiff deadline in an already-filed class action. No new issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"DOCS"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":"moderate — DOCS has retail following"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Robbins LLP issued a shareholder-solicitation notice reminding DOCS investors of the November 16, 2026 lead plaintiff deadline in a securities class action covering purchases from August 8, 2024 through May 13, 2026.\n\nThe complaint alleges Doximity overstated its Newsfeed's contribution to revenue growth while losing market share to competitors with more favorable pricing and engagement models.\n\nThe release recaps three prior stock declines (13%, 17%, and 23%) tied to earlier company disclosures; the notice itself is law-firm marketing, not new information from Doximity.","key_figures":{"customDimensions":{"class_period":"August 8, 2024 to May 13, 2026","lead_plaintiff_deadline":"November 16, 2026"}},"named_entities":{"people":[{"name":"Brian J. Robbins","role":"Founding Partner, Robbins LLP"},{"name":"Aaron Dumas, Jr.","role":"attorney contact, Robbins LLP"}],"products":["Newsfeed"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Doximity, Inc.","ticker":"DOCS","relationship":"litigation target / named issuer"},{"name":"Evercore","relationship":"analyst cited"},{"name":"Jefferies","relationship":"analyst cited"},{"name":"Leerink Partners","relationship":"analyst cited"},{"name":"RBC Capital Markets","relationship":"analyst cited"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T20:35:18.923Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"retailFavoriteBoost":"moderate — DOCS has retail following"}},"durationMs":4910,"modelName":"glm-5.3-flashx"}}